Another new biotech ETF, the ALPS Medical Breakthroughs ETF (NYSEArca: SBIO), also features decent Dyax exposure. The stock is the ETF’s 15th-largest holding at a weight of almost 2.2%, according to issuer data.
SBIO, which debuted on the last day of 2014, tracks the Poliwogg Medical Breakthroughs Index (PMBI), which is comprised “of small-cap and mid-cap pharmaceutical and biotechnology stocks listed on U.S. stock exchanges that have one or more drugs in either Phase II or Phase III U.S. FDA clinical trials,” according to a statement released by ALPS.
Companies with market values in excess of $5 billion do not gain admittance to SBIO. The result is a limited of treatments produced by SBIO holdings having as of yet reached Phase III trials. However, the advantage is the ETF could notch handsome rallies as its holdings navigate the FDA trial process.
The ETF has $52.4 million in assets and is up 20.3% this year.
BioShares Biotechnology Products Fund